ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 2011

A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)

ullrich schwertschlag1, Roy Wu2, yan yang3 and William Shi4, 1Atom Therapeutics, PALO ALTO, CA, 2Atom Bioscience, San Francisco, CA, 3Atom Therapeutics, Suzhou, China (People's Republic), 4Atom Therapeutics, Newark, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: gout, Inflammasome, Inflammation, macrophages

Session Information

Date: Tuesday, October 28, 2025

Title: (1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: ABP-745 is a novel colchicine analogue in development as an anti-inflammatory agent for the treatment of acute gout and other chronic inflammatory conditions. In preclinical models, ABP-745 demonstrated comparable biological activity to colchicine with an improved safety profile including no significant drug-drug interactions.

Methods: Subjects were randomized to active drug or placebo in a 6/2 ratio. Subjects were dosed qd or bid in an ascending order (SAD). SAD Cohorts qd or bid of ABP-745 0.5 mg qd, 1.5 mg qd, 4 mg qd , 5 mg qd and 2.0 mg bid, 2.5 mg bid and placebo (N&#3f32). Multiple ascending dose (MAD, 8 days) cohorts were ABP-745 0.5 mg qd; 1.5 mg qd; 4 mg qd; 2.5 mg bid; 2 mg bid (N&#3f41). Single-dose food effect (ABP-745, 4 mg) was also studied (N&#3f8). Safety was monitored until 3 days post last dose by clinical and laboratory methods. PK was followed over 36 hours (single dose) and on Day 1 (24 h) and Day 8 (36 h) of the MAD regimens.

Results: ABP-745 concentrations were detected 10 minutes post dose across all SAD levels. Maximum ABP-745 mean concentrations peaked between 1.50 h and 2.00 h with biphasic decline across all dose levels. Mean ABP-745 concentrations and exposure parameters (Cmax, AUClast, and AUC0-inf) increased over the 0.5 mg to 5 mg dose range. Mean Cmax ranged from 37.7 ng/mL to 216 ng/mL; mean AUClast ranged from 226 h*ng/mL to 1520 h*ng/mL. Mean ABP-745 Cmax, AUClast, and AUC0-inf increased in a less than proportional manner with increases in single ascending ABP-745 doses. MAD: mean ABP-745 concentrations and exposure parameters (Cmax and AUCτ on Day 1; Cmax,ss and AUCs on Day 8) increased with ascending multiple doses of ABP-745 across study days. On Day 8, mean Cmax,ss ranged from 34.0 ng/mL to 175 ng/mL, mean AUCτ ranged from 181 h*ng/mL to 1230 h*ng/mL. Accumulation ratios for Cmax,ss (RCmax) and AUCτ (RAUCτ) indicated no accumulation in ABP-745 exposure occurred during qd and bid 8-day dose regimens. RCmax values ranged from 0.944 to 1.13 for qd treatments and from 1.15 to 1.24 for bid treatments. On Day 8 approximately 20% of the administered oral dose was recovered in the urine. On Day 1 of MAD, maximum and total ABP-745 exposure (Cmax and AUCτ) generally increased in a less than proportional manner with an increase in multiple ascending QD doses. ABP-745 trough concentrations were higher for bid treatments compared to the qd treatment. Steady-state: Day 2 of dosing for both qd and bid dosing regimens. Food effect (fed/fasted) was studied (N&#3f8). Mean ABP-745 Cmax and AUC0-inf were similar after administration of 4 mg ABP-745 under fed and fasted conditions. Median Tmax was delayed by @ 30 minutes under fed conditions (1.50 h vs. 0.988 h, respectively). Four treatment emergent AEs (TEAE) were reported in the SAD in the 5 mg single dose cohort as gastrointestinal symptoms (single events of diarrhea, nausea, abdominal pain, vomiting). In the MAD cohort 11 TEAE were reported in the 2 highest bid dose groups, such as single cases of nausea, constipation, headache, elevated blood lipase and amylase levels.

Conclusion: Safety and pharmacokinetics (PK) of ABP-745 following single, and multiple qd and bid oral doses in healthy volunteers under fasted and fed conditions further supports development of ABP-745 in an acute gout indication.


Disclosures: u. schwertschlag: ATOMBIOSCIENCE, 2; R. Wu: ATOMBIOSCIENCE, 2; y. yang: ATOMBIOSCIENCE, 3; W. Shi: ATOMBIOSCIENCE, 12,, 3.

To cite this abstract in AMA style:

schwertschlag u, Wu R, yang y, Shi W. A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV) [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-phase-1-placebo-controlled-single-sad-and-multiple-dose-escalation-mad-safety-and-pharmacokinetic-pk-study-of-a-novel-colchicine-analogue-abp-745-in-healthy-volunteers-hv/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-1-placebo-controlled-single-sad-and-multiple-dose-escalation-mad-safety-and-pharmacokinetic-pk-study-of-a-novel-colchicine-analogue-abp-745-in-healthy-volunteers-hv/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology